Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapyJames R. Berenson, Robert Vescio, Youram Nassir et al.|Leukemia|2014Cited by 76
Phase <scp>I</scp>/<scp>II</scp> trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myelomaJames R. Berenson, Debra Mayo, Ori Yellin et al.|British Journal of Haematology|2012Cited by 53
Bendamustine Combined with Bortezomib Has Efficacy in Patients with Relapsed or Refractory Multiple Myeloma: A Phase 1/2 StudyJames R. Berenson, Debra Mayo, Ori Yellin et al.|Blood|2011Cited by 6
Results of a phase I/II study (NCT01365559) of carfilzomib (CFZ) replacing bortezomib (BTZ) in BTZ-containing regimens for BTZ-treated patients (pts) with relapsed and refractory multiple myeloma (MM).James R. Berenson, Robert Vescio, James Hilger et al.|Journal of Clinical Oncology|2013Cited by 3
A Phase 1/2 Study of Carfilzomib As a Replacement for Bortezomib for Multiple Myeloma (MM) Patients (pts) Refractory to a Bortezomib-Containing Combination RegimenJames R. Berenson, Robert Vescio, James Hilger et al.|Blood|2012Cited by 1